LifeSci Startup

TEVOGEN BIO reveals its revenue forecast for its oncology pipeline, emphasizing the company’s unique, faster, and cost-efficient drug development model, which has the potential to serve as a blueprint for sustainable medical innovation in the future. Learn more: https://lnkd.in/gWX3VvK3 #lifescience #biotech #therapeutics #oncology #innovation #revenue

"We're building a company with intentionality. From the lessons [from past experiences], each hire is... Very, very, very vetted" In the 4th and final part of my conversation with eMalick Njie, Ph.D, former founder and CEO of Genetic Leap (who just formed a $409M research partnership with Eli Lilly and Company) and current CEO of Ecotone AI, on The Biotech Startups Podcast, we dive deep into the importance of intentional company building and the lessons learned from past experiences.   Some highlights from our conversation: – 🧠 Ecotone AI's vision for curing rare genetic diseases using AI to understand the human genome 🌟    – 🖥️ The innovative use of diffusion transformers to model genomes and generate synthetic genomic data 🧬    – 👥 The importance of intentional hiring and team building to ensure alignment with the company's vision 🤝   – 🔬 Ecotone's groundbreaking work on DNA Sora, a model aimed at generating synthetic genomes for rare diseases like sickle cell anemia 🩸    – 🔮 The potential future impact of Ecotone's work on understanding life and disease at a fundamental level 🌠    It's super inspiring to hear about the strides Ecotone AI is poised to make in the field of AI and genetics. The potential for transformative breakthroughs in understanding and treating rare genetic diseases is absolutely massive.   eMalick Njie, Ph.D also took a moment to express gratitude to those who've supported him along the way. He thanked his supervisors Wendy Smith, Alice Ting, David Borchelt, Jake, and Marty Chalfie for their guidance. He gave a heartfelt shout-out to his parents and sister for fostering his curiosity, and to his best friend Wilton Williams for his encouragement and support. eMalick also acknowledged his New York crew, particularly Greg and Mike, as well as his investors. It's clear that behind every great innovator is a strong support network 🙏    If you're interested in getting involved, Ecotone is opening their seed round shortly. Interested investors can contact invest@ecotone.ai Apple Podcasts & Spotify links in the comments below 👇🏽    #biotechnology #lifesciences #podcast #AI #genetics

Eli Lilly and Company and insitro form unique AI Partnership, aiming for innovative treatments for metabolic diseases. insitro will in-license Lilly’s delivery technology for its investigational liver-targeted siRNA therapies. The pharma will be eligible for milestones and royalties down the line. Learn more: https://lnkd.in/geYnP3CJ #lifescience #biotech #AI #healthnews #pharma

John Maraganore, former CEO of Alnylam Pharmaceuticals, has launched his latest venture, City Therapeutics, with $135 million in backing from top investors including ARCH Venture Partners, Fidelity, and Regeneron Ventures. City Therapeutics is focused on building an siRNA-engineering platform to design and optimize RNAi-based medicines, aiming to silence genes and stop the production of harmful proteins. Learn more: https://lnkd.in/gygNfXyV #lifescience #biotech #health #medicine #engineering

Gene therapy pioneer Jim Wilson launches Franklin Biolabs, backed by Savanne Life Sciences. Wilson aims to drive innovative research and develop transformative therapies for severe conditions. Learn more: https://lnkd.in/eAkEXT-r #Biotech #GeneTherapy #FranklinBiolabs #Lifescience #Innovation

Biomea Fusion, a clinical-stage biopharmaceutical company, today announced the formation of Biomea Fusion’s Global Scientific Advisory Board (SAB) with internationally renowned experts in beta cell science and diabetes therapeutics. Learn more: https://lnkd.in/gepERy5c #biotech #lifescience #Diabetes #CellScience

Biomea Fusion, a clinical-stage biopharma company focused on developing oral treatments for metabolic diseases and genetically defined cancers, announced that the #FDA has lifted the clinical hold on its Phase I/II trials for BMF-219, a covalent menin inhibitor. These trials, COVALENT-111 and COVALENT-112, are investigating the drug for the treatment of type 2 and type 1 diabetes, respectively. More: https://lnkd.in/gVr5jSrA #lifescience #biotech #diabetes #healthnews

Nanostics and Protean Launch CDX Prostate for Men at Risk of Aggressive Prostate Cancer. CDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. Learn more: https://lnkd.in/gfBHUX33 #AI #cancer #healthnews #lifescience #data

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic #Dermatitis Learn more: https://lnkd.in/g9ztR-xr #lifescience #biotech #biotherapeutics

A global biotech leader selected Philly's Navy Yard for their new innovation lab. On Wednesday, French molecular diagnostics company bioMérieux opened its new genomics and innovation center. The 32,000-square-foot facility will feature state-of-the-art lab, office, and manufacturing spaces. Learn more: https://lnkd.in/gkvwtJkc #lifescience #biotech #innovation #genomics